WeVote

Bill

Bill

SF 1023

Inherited metabolic diseases coverage by health plans requirement provision

2025-2026 Regular Session Introduced by Jim Abeler and 4 co-sponsors

Minnesota bill mandates health insurance coverage for inherited metabolic disease screening, diagnosis, and treatment to ensure access for rare genetic condition patients.

Referred to Commerce and Consumer Protection
0
WeVote Research Nonpartisan
Bill Summary · SF 1023

Legislative bill overview

SF 1023 requires health insurance plans in Minnesota to provide coverage for screening, diagnosis, and treatment of inherited metabolic diseases. The bill establishes mandated benefits that insurers must include in their health plans, ensuring patients with these rare genetic conditions have access to necessary medical interventions without coverage denial.

Why is this important

Inherited metabolic diseases are rare but serious genetic conditions that can cause severe disability or death if left untreated. Many affected families face significant out-of-pocket costs or coverage denials, making early detection and treatment inaccessible. This mandate would standardize coverage across plans, improving outcomes for patients with conditions like phenylketonuria (PKU), maple syrup urine disease, and other metabolic disorders.

Potential points of contention

  • Cost impact on insurers and premiums: Mandated benefits typically increase insurance costs; insurers may argue this raises premiums for all enrollees to cover a small population
  • Definition scope and clarity: The bill's definition of "inherited metabolic diseases" may be unclear, potentially leading to coverage disputes or disputes about which conditions qualify
  • Coordination with existing programs: Minnesota already has newborn screening requirements; unclear how this mandate coordinates with existing public health infrastructure and whether it creates redundancy or gaps

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.